The NASH Market

Current market is comprised entirely of off-label use of therapeutics approved for other diseases including:

Dumbbells
  • Diet
  • Exercise
Pills
  • Supplements
  • Omega-3 Fatty Acids
  • Vitamin E
Prescription
  • Insulin Sensitizers
  • Metformin
Close
  • Ineffective for decompensated liver patients

13.8MM

United States prevalence*

68.8%

Compound Annual Growth Rate

26.1MM
in 7MM

Global prevalence*

Shield

Early (Pre-Clinical or Phase I/II) development acquisition activity is robust

*Global market data, 2020

Contact Us